CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

RT-PCR Covid-19Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2147 SARSCoV2 Convalescent Plasma Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D014777 Virus Diseases NIH 0.12
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Incidence of Covid-19 in School Children During the Pandemic Period in Nice

The Coronavirus disease 2019 (COVID-19) is causing a global pandemic with high morbidity and mortality among adults and mainly the elderly. Children seem to be little or not affected by this infection. It is estimated that children could be asymptomatic or pauci-symptomatic carriers and thus be vectors of the disease. This is why measures to close schools and confine populations have been decreed in a large number of countries, including France. However, there are only a few data on the prevalence of COVID19 disease in children. The deconfinement strategy depends on data on the prevalence of the disease, especially in children. Investigators propose to evaluate the incidence of Covid-19 in preschool and elementary schools children in the city of Nice (South of France) during the pandemic period using a local prospective study of 914 children

NCT04377737 Infection; Viral, Coronavirus Diagnostic Test: RT-PCR Covid-19
MeSH:Coronavirus Infections Virus Diseases

Primary Outcomes

Description: measure by two rt-PCR COVID-19 tests regardless the serological status of the child

Measure: evaluation of the prevalence of positive real-time-polymerase chain reaction (rt-PCR) in school children during the pandemic period in Nice

Time: at 42 days

Secondary Outcomes

Description: measure by two serological COVID-19 test (IgG and/or IgM)

Measure: evaluation of the serological prevalence of the Covid-19 infection

Time: at inclusion and at 42 days

Description: measure by two serological COVID-19 test (IgG and/or IgM)

Measure: evaluation of the COVID-19 reinfection among seropositive children at the inclusion time

Time: at inclusion and at 42 days

Description: positivity of rt-PCR test for other viruses (adenovirus, metapneumovirus, picornavirus, respiratory syncytial virus, influenza et parainfluenza and other coronavirus strains)

Measure: evaluation of the prevalence of positive rt-PCR of other respiratory viruses (including others coronavirus)

Time: at 42 days

Description: measure of level of the two inflammation biomarkers (IFIT1 interferon and CCL8)

Measure: comparison of inflammatory response level between different coronavirus strains

Time: at 42 days

Description: measure of the medico-social relative risk associated with rt-PCR COVID-19 test positivity among : school level, gender, school type, day care facilities before 11th May, number of siblings, housing type, number of bedrooms, precariousness level, by score EPICES ( (Evaluation de la Précarité et des Inégalités de santé dans les Centres d'examens de santé, means Assessment of precariousness and health inequalities in health examination centers). Questionnaire of EPICES counts 11 items, the answer to each question is assigned a coefficient, the sum of the 11 answers gives the score EPICES. The score is continuous, it varies from 0 (lack of precariousness) to 100 (maximum precariousness).

Measure: Estimation of medico-social risk factors associated with COVID-19 infection

Time: at 42 days

No related HPO nodes (Using clinical trials)